• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CORRECTING and REPLACING Provectus Pharmaceuticals, Inc. Retains The Investor Relations Group of New York

Posted on: Tuesday, 13 March 2007, 12:01 CDT

Ticker in first graph should read (OTCBB: PVCT) (sted (OTCBB: PVTC)).

The corrected release reads: 

PROVECTUS PHARMACEUTICALS, INC. RETAINS THE INVESTOR RELATIONS GROUP OF NEW YORK

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has retained The Investor Relations Group, Inc. (IRG), a full-service investor relations firm, to serve as its new investor relations and corporate communications agency.

"As Provectus continues to make progress towards gaining FDA approval for our ground-breaking cancer treatment (Provecta™) and our topical hydrogel for psoriasis and eczema (Xantryl™), and as interest within the investment community for the drugs in our pipeline escalates, we felt it was in the best interest of the company and its shareholders to retain the services of The Investor Relations Group in order to fully communicate our message to the investing public," said Craig Dees, Ph.D., Chief Executive Officer of Provectus Pharmaceuticals, Inc. "With such important implications pending on the approval of our breakthrough therapies and their potential to affect the lives of hundreds of thousands of people, we believe a strategic relationship with the right investor relations firm is pivotal in accomplishing our goals."

IRG will strive to increase investor and industry awareness of Provectus within the capital markets by introducing the Company and its Management to pre-qualified fund managers and industry analysts. Further, the corporate communications arm of IRG will help shape the company's message and manage its communications to the public and to the media-at-large.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus takes a macroscopic, or "big picture", approach by applying small-molecule drugs that target diseased tissue, allowing the therapy to selectively attack broad classes of disease. This opposes current industry trends that take a molecular (microscopic) approach. Provectus is currently conducting clinical trials of its proprietary drugs Provecta™ (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl™, a topical treatment for severe psoriasis and eczema. The Provecta Phase 1 clinical trial for melanoma is nearing completion and the company expects to move quickly into Phase 2. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Initial Phase 1 clinical trial objectives for Provecta for breast cancer were completed in April 2006, but the trial was extended to more properly determine optimal dosing. The extended Phase 1 trial is also nearing completion and the company anticipates reporting those results in the near future. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. Complementing its suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnology. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.

About The Investor Relations Group

The Investor Relations Group, Inc. (IRG), founded in 1996, represents select publicly traded companies, with a unique specialization for assisting those in the small-cap sector. IRG arranges one-on-one meetings for its portfolio companies with pre-qualified money managers handling investment portfolios that range from $10 million to $10 billion+ selected from its proprietary contact base of over 70,000 qualified fund managers who have an investing history in small cap stocks. IRG's corporate communications services include writing all press releases and shareholder communications and serving as primary contact for the investing community, with the focus of building awareness of its companies within the financial and trade media, as well as the public at large. For further information, please visit the company's website at http://www.investorrelationsgroup.com.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Source: Business Wire

More News in this Category